Perspective Therapeutics, Inc. Common Stock
CATX56
$15.26arrow_drop_down1.16%-$0.18
CATX56
$15.26
arrow_drop_down1.16%Performance History
| Key Stats | |
|---|---|
| Open | $15.49 |
| Prev. Close | $15.44 |
| EPS | -1.47 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 14.51 | 15.64 |
| 52 Week Range | 2.10 | 19.10 |
| Ratios | |
|---|---|
| Revenue | - |
| EBITDA Margin % | - |
| EPS | -1.47 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Perspective Therapeutics, Inc. Common Stock (CATX)
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Mr. Johan M. Spoor
- Headquarters
- Richland
- Employees
- 91
- Exchange
- NYSE
Keep an eye on Perspective Therapeutics, Inc. Common Stock
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Perspective Therapeutics, Inc. Common Stock's (CATX) price per share?
The current price per share for Perspective Therapeutics, Inc. Common Stock (CATX) is $15.26. The stock has seen a price change of -$0.18 recently, indicating a -1.17% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Perspective Therapeutics, Inc. Common Stock (CATX)?
For Perspective Therapeutics, Inc. Common Stock (CATX), the 52-week high is $19.1, which is 25.16% from the current price. The 52-week low is $2.1, the current price is 626.67% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Perspective Therapeutics, Inc. Common Stock (CATX) a growth stock?
Perspective Therapeutics, Inc. Common Stock (CATX) has shown an average price growth of 0.41% over the past three years. It has received a score of 93 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Perspective Therapeutics, Inc. Common Stock as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Perspective Therapeutics, Inc. Common Stock (CATX) stock price performance year to date (YTD)?
As of the latest data, Perspective Therapeutics, Inc. Common Stock (CATX) has a year-to-date price change of 280.36%. Over the past month, the stock has experienced a price change of 23.36%. Over the last three months, the change has been 18.29%. Over the past six months, the figure is 49.61%.
help
Is Perspective Therapeutics, Inc. Common Stock (CATX) a profitable company?
Perspective Therapeutics, Inc. Common Stock (CATX) has a net income of -$46.51M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -2.71K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$40.94M. Furthermore, the EBITDA is -$47.27M.
help
What is the market capitalization of Perspective Therapeutics, Inc. Common Stock (CATX)?
Perspective Therapeutics, Inc. Common Stock (CATX) has a market capitalization of $1.02B. The average daily trading volume is 824.5K, indicating the stock's liquidity and investor engagement.
News
PERSPECTIVE THERAPEUTICS
PRICE TARGETS
STOCK PERFORMANCE
7/16/2024Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet - Zacks Investment Research
COMPANY ANNOUNCEMENT
6/12/2024Perspective Therapeutics Announces Inclusion in the Russell 3000® Index
COMPANY ANNOUNCEMENT
6/10/2024Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
COMPANY ANNOUNCEMENT
5/24/2024Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
CALENDAR OF EVENTS
5/20/2024Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
COMPANY ANNOUNCEMENT
5/3/2024Perspective Therapeutics to Participate at Upcoming May Investor Conferences